pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Rare Disease · news · pharmadog
← back to Rare Disease
News mentioning Rare Disease
221
stories
16d
STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more
stat
16d
MRI is standard for diagnosing prostate cancer in most western countries. But most U.S. men don’t get them
stat
16d
STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds
stat
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
16d
STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
stat
17d
STAT+: The latest orphan drug exemptions may not be warranted, analysis finds
stat
17d
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
18d
Amgen hit with cybersecurity breach, patient data affected
biospace
18d
Heart transplant candidates fail if they get too weak. New program tries inpatient prehab
stat
18d
STAT+: Are AI scribes useful tools in medical education, or a crutch that imperils learning?
stat
18d
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
18d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
21d
UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma
biospace
21d
Federal government could improve infectious disease monitoring, says federal government
stat
21d
Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail
fiercebiotech
21d
Opinion: Limb girdle muscular dystrophy patients face a maddening reality
stat
21d
Alnylam plunges as earnings deliver ‘one-two punch’
biopharma dive
22d
Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemption
stat
22d
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
22d
Is it safe to drink Red Bull and alcohol? Questionable research tied to energy drink giant has shaped policy
stat
22d
Capricor Duchenne cell therapy voted down by FDA panel
biopharma dive
22d
FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute
fiercebiotech
22d
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
biopharma dive
23d
Do you need oncology experience to land an oncology job?
biospace
23d
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
biospace
23d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
23d
STAT+: Bracing for another Fauci hearing
stat
24d
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
24d
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
biospace
24d
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
biospace
← prev
page 3 of 8
next →
